Philips iFR technology

October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major outcomes compared with waiting for follow-upAdditional results from the ILIAS ANOCA study highlight the sustained benefits of physiology-guided assessment and tailored medical therapy for patients with angina and no obstructive coronary arteries Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced late-breaking results from the iMODERN trial (Instantaneous wave-free Ratio Guided Multivessel Revascularisation During PCI for Acute Myocardial Infarction) at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference, the world’s leading meeting for interventional cardiology. The study compared immediate versus delayed treatment of additional narrowed arteries in heart attack patients to determine whether treating all blockages in one procedure is as safe and effective as waiting for a follow-up procedure. The study compared immediate versus deferred treatment of additional narrowed arteries in heart attack patients to determine whether treating all blockages in a single procedure is superior to waiting for a follow-up procedure – a key question, since many patients have multiple diseased arteries and the optimal timing for complete treatment remains uncertain. In today’s practice, when patients suffer a serious type of heart attack (STEMI), cardiologists urgently open the blocked artery causing the attack. But many of these patients also have disease in other arteries. Often these additional narrowed arteries are not treated right away, either due to time restraints, patient stability, resource constraints or because they stay unnoticed. They may be treated later in a separate hospital stay or not at all, leaving uncertainty about the best timing and approach. The new findings show that patients can safely have additional arteries treated immediately during the first procedure to treat the acute event, rather than during a later second intervention. By confirming the safety of extending Class I, Level A-recommended iFR to non-stable patients, the results offer physicians the opportunity to complete treatment in one session, without compromising long-term outcomes. The iMODERN trial is the largest study to date testing iFR* in the acute heart attack setting, expanding the evidence base for a tool already strongly recommended (Class I, Level A) in stable patients. The findings are published in The New England Journal of Medicine (NEJM), underscoring its global scientific significance and impact on cardiology practice. “These results address one of the longest-standing questions in interventional cardiology,” said Prof. Niels van Royen, co-principal investigator, Radboud University Medical Center, The Netherlands. “Measuring and eventually treating additional arteries can be performed during the first procedure or during a staged procedure. That means cardiologists can feel confident offering patients a complete solution in one sitting when it’s appropriate.” The iMODERN study enrolled 1,146 patients across 41 hospitals in 14 countries directly addressed this question. Patients were randomly assigned to one of two treatment strategies: either immediate physiology-guided treatment of additional narrowed arteries during the first procedure using instantaneous wave-free ratio (iFR), or staged treatment guided by cardiac Magnetic Resonance Imaging (MRI) carried out within four days to six weeks after the heart attack. The study’s main endpoint combined three outcomes: death, another heart attack, or hospitalization for heart failure over three years. After three years of follow-up, the trial found no significant difference in major outcomes – including death, repeat heart attack, or hospitalization for heart failure – between the two approaches. By confirming that both approaches are backed by solid evidence, the trial offers patients more certainty and more personalized care. “Flexibility is critical in real-world practice,” added Prof. Dr. Robin Nijveldt, co-principal investigator, at Radboud University Medical Center, in the Netherlands. “Some patients may benefit from immediate treatment, while others are better served by waiting. iMODERN is a pragmatic study that shows that an immediate intervention is not necessarily better than waiting, if patients are offered a CMR to evaluate the need for a second intervention, giving physicians the evidence they need to tailor decisions to each patient.” “These results complement current international guideline recommendations (Class I recommendation, Level A evidence) for complete revascularization in STEMI,” said Dr. Darshan Doshi, practicing interventional cardiologist and Head of Medical & Clinical at Philips Image-Guided Therapy Devices. “By integrating physiological assessment, iMODERN’s evidence demonstrates that cardiologists can follow these findings for full revascularization while also tailoring treatment to each vessel’s true ischemic relevance.” Complementary evidence from ILIAS ANOCA In related findings presented at the same conference, the ILIAS ANOCA (Inclusive Invasive Physiological Assessment in Angina Syndromes – Angina with No Obstructive Coronary Artery Disease) study further demonstrated the value of physiology-guided decision-making — this time in patients with angina and no obstructive coronary arteries (ANOCA). The ILIAS ANOCA study evaluated the impact of coronary function testing (CFT) in patients whose coronary arteries appear unobstructed on angiography but who continue to experience angina. Conducted across five cardiac centers in the Netherlands and Germany (n=153), the investigator-initiated, randomized, blinded-arm controlled trial compared standard care with CFT-guided medical therapy using Philips Doppler FloWire and FloMap systems. The study found that ad-hoc CFT followed by tailored therapy significantly improved patient-reported angina symptoms and quality of life at six months, with a mean 9.4-point gain in the Seattle Angina Questionnaire summary score (95% CI 3.9–14.9; p=0.001). There were no procedure-related complications or major adverse cardiac events. These results confirm and extend the earlier CorMiCA findings, supporting CFT as a Class I, Level A recommendation in ANOCA patients and demonstrating the potential of Philips Doppler technology to guide individualized treatment strategies safely and effectively. The 12-month results presented on October 26th demonstrate the sustained benefits of CFT-guided care. iFR and MRI technologyPhilips physiology solutions – including its instantaneous wave-free ratio (iFR) pressure wires and software – were used to guide immediate treatment decisions in the trial. Philips also provides advanced cardiac MRI technology, which guided the delayed strategy. By enabling both the invasive and non-invasive approaches evaluated in iMODERN, Philips supported the generation of robust evidence to help guide clinical practice worldwide. * iFR (instantaneous wave-free ratio) is a minimally invasive way to measure blood pressure through the coronary arteries, helping physicians decide which blockages require stenting. For further information, please contact: Joost MalthaPhilips Global External RelationsTel.: +31 6 1055816E-mail: joost.maltha@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment

Philips iFR technology

Philips Follow C-arm capability

Follow C-arm

October 27, 2025                                                    New integration of Philips Advanced Visualization Workspace* with the Azurion image-guided therapy platform automatically synchronizes CT images with C-arm movement, supporting workflow efficiency and additional anatomical insights in PCI procedures1 San Francisco, USA and Amsterdam, The Netherlands – At the annual Transcatheter Cardiovascular Therapeutics (TCT 2025) meeting, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced an industry-first innovation that integrates pre-operative CT data directly into the cath lab workflow. This new capability, available through the integration of Philips’ Advanced Visualization Workspace (AVW) with the Azurion image-guided therapy system, marks a first step towards CT-guided percutaneous coronary intervention (PCI), a minimally invasive procedure to open narrowed coronary arteries and restore blood flow to the heart.The new capability, Follow C-arm, automatically synchronizes the 3D reconstruction of coronary arteries with the movement of the Azurion C-arm. As the C-arm angulation changes, the CT volume rotates in real time to match, giving interventionalists the 3D anatomical view without manual interaction. This seamless connection helps clinicians combine the detailed insights of CT imaging with the flexibility of live X-ray guidance inside the cath lab. The combined AVW–Azurion approach aims to provide enhanced anatomical insights to guide complex PCI procedures, publications have shown that leveraging CCTA may lead to reduction in contrast medium use and radiation dose during interventions.1Supporting the shift towards CT-guided PCICoronary computed tomography angiography (CCTA) is increasingly used in global clinical guidelines as a first-line tool for the diagnosis and planning of coronary artery disease. With more patients now arriving at the cath lab with prior CT scans, physicians are seeking ways to incorporate this information into their interventional workflows. By integrating CT data directly into Azurion, Philips is helping interventionalists expand the use of CT beyond diagnosis and planning, supporting a future in which CT-guided PCI becomes standard practice.“By bringing pre-operative CT into the cath lab and linking it directly to the movement of the C-arm, Philips is delivering an industry-first that helps interventionalists prepare for and execute PCI procedures with greater confidence,” said Mark Stoffels, Business Leader Image-Guided Therapy Systems at Philips. “This seamless integration is a significant step towards CT-guided PCI, aligning with our commitment to improving workflow efficiency and advancing patient care in interventional cardiology.”The launch builds on the global success of Philips’ Azurion image-guided therapy platform, the world’s leading system designed for seamless integration of advanced applications. Since its introduction in 2017, Azurion has been used to treat more than 6.4 million patients annually in over 80 countries, helping physicians perform minimally invasive procedures with greater confidence and efficiency.For more information about Philips’ presence at TCT, please visit the Philips TCT 2025 landing page. For further information, please contact:Joost MalthaPhilips Global External RelationsTel.: +31 6 1055816E-mail: joost.maltha@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Disclaimer: * The Follow C-arm capability as part of Philips Advanced Visualization Workspace may not be available in all markets. Please contact your Philips representative for more details.Reference: 1. J Cardiovasc Comput Tomogr. 2025 May-Jun;19(3):277-290.

Attachments

Philips Follow C-arm capability

Follow C-arm